Stratos Wealth Partners LTD. Sells 242 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Stratos Wealth Partners LTD. lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,651 shares of the medical equipment provider’s stock after selling 242 shares during the period. Stratos Wealth Partners LTD.’s holdings in Zimmer Biomet were worth $789,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. Ameriprise Financial Inc. lifted its holdings in Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock worth $517,039,000 after purchasing an additional 3,208,596 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after buying an additional 1,488,918 shares in the last quarter. Nuveen LLC bought a new position in shares of Zimmer Biomet in the first quarter valued at approximately $155,891,000. Alyeska Investment Group L.P. purchased a new position in Zimmer Biomet during the first quarter valued at approximately $101,294,000. Finally, Dodge & Cox grew its stake in Zimmer Biomet by 2.3% during the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after acquiring an additional 446,018 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.39% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on ZBH. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Redburn Partners set a $130.00 price objective on Zimmer Biomet in a research note on Thursday, September 18th. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Royal Bank Of Canada set a $111.00 price target on Zimmer Biomet in a report on Friday, October 10th. Finally, Rothschild & Co Redburn assumed coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a “buy” rating and a $130.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $111.94.

Zimmer Biomet Trading Up 1.2%

Shares of ZBH stock opened at $103.87 on Thursday. The business has a 50-day moving average price of $101.83 and a two-hundred day moving average price of $97.72. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The firm has a market cap of $20.58 billion, a P/E ratio of 25.27, a price-to-earnings-growth ratio of 2.36 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company’s revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio is 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.